New drug combo aims to keep blood cancer at bay longer
NCT ID NCT06104566
Summary
This global study is testing whether adding a new drug called lisaftoclax to a standard cancer therapy (BTK inhibitor) works better for controlling chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in patients who have already been on that standard therapy. About 400 adults with CLL/SLL who have been on BTK inhibitor treatment for at least a year will be randomly assigned to receive either the standard therapy alone or the standard therapy plus lisaftoclax. The main goal is to see if the combination helps keep the cancer from getting worse for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL/SLL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaluga Regional Clinical Research
RECRUITINGKaluga, 246007, Russia
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Conditions
Explore the condition pages connected to this study.